Ratings PolyNovo Limited

Equities

PNV

AU000000PNV0

Market Closed - Australian S.E. Other stock markets 11:40:44 26/04/2024 am IST			5-day change	1st Jan Change
1.99 ^AUD	-4.78%		+2.31%	+20.24%

04/03	Polynovo Gets India OK for Listing of Dermal Scaffold Device on Government e-Portal Marketplace	MT
27/02	Transcript : PolyNovo Limited, H1 2024 Earnings Call, Feb 27, 2024

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The company's profit outlook over the next few years is a strong asset.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For several months, analysts have been revising their EPS estimates roughly upwards.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 330.02 times its estimated earnings per share for the ongoing year.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
POLYNOVO LIMITED	+20.24%	896M	C
ABBOTT LABORATORIES	-2.31%	187B	C+
MEDTRONIC PLC	-3.20%	106B	C
BECTON, DICKINSON AND COMPANY	-5.04%	66.9B	A
DEXCOM, INC.	+0.20%	49.45B	B-
CENCORA, INC.	+17.29%	48B	B-
HOYA CORPORATION	+4.06%	40.84B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.48B	B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.25B	A-
TERUMO CORPORATION	+12.96%	24.62B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes